Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach

Arthritis and Rheumatism

Volumn 56, Issue 10, 2007, Pages 3420-3432

  Lefranc, Didier ^a   Launay, David ^b   Dubucquoi, Sylvain ^a   De Seze, Jérôme ^b   Dussart, Patricia ^a   Vermersch, Marie ^a   Hachulla, Eric ^a   Hatron, Pierre Yves ^a   Vermersch, Patrick ^b   Mouthon, Luc ^c   Prin, Lionel ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ANTIGEN; GAG PROTEIN; HEAT SHOCK PROTEIN 70; MICROTUBULE ASSOCIATED PROTEIN 2; MICROTUBULE ASSOCIATED PROTEIN 2B; SEPTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; MALE; MICROTUBULE; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BLOTTING, WESTERN; BRAIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 35348916784     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22863     Document Type: Article

References (53)

1. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58:1214-20.
2. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001;45:419-23.
3. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al, for the Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265-73.
4. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
5. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 2005;19:799-821.
6. Senecal JL, Raymond Y. The pathogenesis of neuropsychiatric manifestations in systemic lupus erythematosus: a disease in search of autoantibodies, or autoantibodies in search of a disease? J Rheumatol 2004;31:2093-8.
7. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000;9:498-503.
8. Tomita M, Khan RL, Blehm BH, Santoro TJ. The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus. Med Hypotheses 2004;62:325-35.
9. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007;56:1242-50.
10. Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005;52:1670-5.
11. Okamoto H, Katsumata Y, Nishimura K, Kamatani N. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004;50:3731-2.
12. Iikuni N, Okamoto H, Yoshio T, Sato E, Kamitsuji S, Iwamoto T, et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 2006;65:253-6.
13. Buyon JP. Neonatal lupus. Curr Opin Rheumatol 1996;8:485-90.
14. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007;36:297-315.
15. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93.
16. Rice JS, Kowal C, Volpe BT, DeGiorgio LA, Diamond B. Molecular mimicry: anti-DNA antibodies bind microbial and nonnucleic acid self-antigens. Curr Top Microbiol Immunol 2005; 296:137-51.
17. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A 2006;103:678-83.
18. Yoshio T, Onda K, Nara H, Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006;54:675-8.
19. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006;54:2515-22.
20. Williams RC Jr, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004;50:1239-47.
21. Lefranc D, Almeras L, Dubucquoi S, de Seze J, Vermersch P, Prin L. Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. J Immunol 2004;172: 669-78.
22. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
23. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lunlin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
26. Hochstrasse DF, Merril CR. 'Catalysts' for Polyacrylamide gel polymerization and detection of proteins by silver staining. Appl Theor Electrophor 1988;1:35-40.
27. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from Polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76: 4350-4.
28. Marshall G, Baron AE. Linear discriminant models for unbalanced longitudinal data. Stat Med 2000;19:1969-81.
29. Henzel WJ, Billeci M, Stults JT, Wong SC, Grimley G, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci U S A 1993;90:5011-5.
30. Almeras L, Lefranc D, Drobecq H, de Seze J, Dubucquoi S, Vermersch P, et al. New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 2004; 4:2184-94.
31. Zephir H, Almeras L, El Behi M, Dussart P, de Seze J, Steibel J, et al. Diversified serum IgG response involving non myelin CNS proteins during experimental autoimmune encephalomyelitis. J Neuroimmunol 2006;179:53-64..
32. Mouthon L, Haury M, Lacroix-Desmazcs S, Barreau C, Coutinho A, Kazatchkine M. Analysis of the normal human IgG antibody repertoire: evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J Immunol 1995;154:5769-78.
33. Sobel ES, Kakkanaiah VN, Kakkanaiah M, Cheek RL, Cohen PL, Eisenberg RA. T-B collaboration for autoantibody production in lpr mice is cognate and MHC-restricted. J Immunol 1994;152: 6011-6.
34. Francoeur AM, Heitzmann JG. Autoantibodies: terms and concepts. Clin Immunol Immunopathol 1988;47:245-52.
35. Ferreira C, Mouthon L, Nobrega A, Haury M, Kazatchkine MD, Ferreira E, et al. Instability of natural antibody repertoires in systemic lupus erythematosus patients, revealed by multiparametric analysis of serum antibody reactivities. Scand J Immunol 1997;45:331-41.
36. Schwartz M. Physiological approaches to neuroprotection: boosting of protective autoimmunity. Surv Ophthalmol 200I;45 Suppl 3:S256-60.
37. Kowal C, DeGiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2007; 103:19854-9.
38. Kinoshita M, Noda M. Roles of septins in the mammalian cytokinesis machinery. Cell Struct Funct 2001;26:667-70.
39. Kremer BE, Haystead T, Macara IG. Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4. Mol Biol Cell 2005;16:4648-59.
40. Margutti P, Sorice M, Conti F, Delunardo F, Racaniello M, Alessandri C, et al. Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations. Arthritis Res Ther 2005;7:R896-903.
41. Senecal JL, Rauch J, Grodzicky T, Raynauld JP, Uthman I, Nava A, et al. Strong association of autoantibodies to human nuclear lamin B1 with lupus anticoagulant antibodies in systemic lupus erythematosus. Arthritis Rheum 1999;42:1347-53.
42. Shoenfeld Y, Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential [review]. Arthritis Rheum 2005;52:2599-606.
43. Maccioni RB, Cambiazo V. Role of microtubule-associated proteins in the control of microtubule agency. Physiol Rev 1995;75: 835-64.
44. Orosz O, Wagner G, Liliom K, Kovacs J, Baroti K, Horanyi M, et al. Enhanced association of mutant triosephosphate isomerase to red cell membranes and to brain microtubules. Proc Natl Acad Sci U S A 2000;97:1026-31.
45. Sheline CT, Choi DW. Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. Neurobiol Dis 1998;5:47-54.
46. Hollan S, Fujii H, Hirono A, Karro H, Miwa S, Harsanyi V, et al. Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers one with and one without neurological symptoms. Hum Genet 1993;92:486-90.
47. Sasajima T, Watanabe H, Sato S, Sato Y, Ohira H. Anti-triosephosphate isomerase antibodies in cerebrospinal fluid are associated with neuropsychiatric lupus. J Neuroimmunol 2006;181: 150-6.
48. Watanabe H, Seino T, Sato Y. Antibodies to triosephosphate isomerase in patients with neuropsychiatric lupus. Biochem Biophys Res Commun 2004;321:949-53.
49. Dhillon VB, McCallum S, Norton P, Twomey BM, Erkeller-Yuksel F, Lydyard P, et al. Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus. Ann Rheum Dis 1993;52:436-42.
50. Van der Weerd L, Lythgoe MF, Badin RA, Valentim LM, Akbar MT, de Belleroche JS, et al. Neuroprotective effects of HSP70 overexpression after cerebral ischaemia - an MRI study. Exp Neurol 2005;195:257-66.
51. Conroy SE, Tucker L, Latchman DS, Isenberg DA. Incidence of anti Hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis. Clin Exp Rheumatol 1996;14: 99-104.
52. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr Res 2001;52:127-65.
53. Chiba S, Yokota SI, Yonejura K, Tanaka S, Furuyama H, Kubota H, et al. Autoantibodies against HSP 70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J Neurol Sci 2006;241:39-43.